ProteinChip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 5-6, 1999, Pages 264-276

  Wright Jr , G L ^a,b   Cazares, L H ^a,b   Leung, S M ^c   Nasim, S ^a,b   Adam, B L ^a,b   Yip, T T ^a,c   Schellhammer, P F ^a,b   Gong, L ^a,b   Vlahou, A ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Sentara Cancer Resource Centers   (United States)

^c CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

Biomarkers; Mass spectrometry; Prostate cancer; ProteinChip ; Proteins; SELDI immunoassay; Surface laser enhanced ionization desorption

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; BIOTECHNOLOGY; CANCER DIAGNOSIS; CANCER STAGING; CELL LYSATE; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; SEMINAL PLASMA;

EID: 0011063449     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500384     Document Type: Article

References (27)

1. Mitchell EP. Role of carcinoembryonic antigen in the management of advanced colorectal cancer. Sem Oncol 1998; 25: 12-20.
2. Schmoll HJ, Beyer J. Prognostic factors in metastatic germ cell tumors. Sem Oncol 1998; 25: 174-185.
3. Bartlett NL, Freiha FS, Torti FM. Serum markers in germ cell neoplasms. Hematol Oncol Clin N Am 1991; 5: 1245-1260.
4. Osterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-923.
5. Pannek J, Partin AW. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prstate cancer. Sem Urol Oncol 1998; 16: 100-105.
6. Vashi AR et al. Determination of the "reflex range" and appropriate cutpoints for percent free PSA in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49: 19-27.
7. Hillenkamp F, Karas M, Reavis RC, Chait BT. Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. Anal Chem 1991; 63: 1193-1202.
8. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993; 7: 576-580.
9. Hutchens TW, Yip TT. Affinity mass spectrometry. Protein Sci 1993; 2: 92.
10. Yip T-T et al. Cryptic antigenic determinants on the extracellular pyruvate dehyrogenase complex/mimeotope found in primary biliary cirrhosis. J Biol Chem 1996; 271: 32825-32833.
11. Kuwata H, Yip T-T, Yip CL, Tomita M, Hutchens TW. Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun 1998; 245: 764-773.
12. Abrahamsson PA, Lilja H. Three predominant prostatic proteins. Andrologia 1990 (Suppl); 1: 122-121.
13. Epstein JI. PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin N Am 1993; 20: 757-770.
14. Troyer JK, Beckett ML, Wright Jr GL. Detection and characterization of the prostate specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995; 62: 552-558.
15. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of human prostate specific antigen. Invest Urol 1979; 17: 159-164.
16. Wright Jr GL et al. Generation and characterization of monoclonal antibodies to prostate secretory protien. Int J Cancer 1990; 46: 39-49.
17. Emmert-Buck MR et al. Laser capture microdissection. Science 1996; 274: 998-1001.
18. Kamada M et al. Beta-microseminoprotein/prostatic secretory protein is a member of immunoglobulin binding factor, family. Biochim Biophys Acta 1998; 1388: 101-110.
19. Lee C et al. Two-dimensional characterization of prostatic acid phosphatase, prostatic specific antigen and prostate binding protein in expressed prostatic fluid. Prostate 1986; 9: 135-146.
20. 1-antichymotrypsin complexed m vitro. Biotechnol Appl Biochem 1998; 27: 249-257.
21. Wright Jr GL, Haley C, Beckett ML, Schellhammer, PF. Expression of prostate-specific membrane, antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995; 1: 18-28.
22. Wright Jr GL et al. Upregulation of prostate specific membrane antigen (PSMA) following androgen deprivation therapy. Urology 1996; 48: 326-334.
23. Paweletz OP et al. A novel proteomic approach to monitor carcinogenic disease progression using surface enhanced desorption ionization spectroscopy (SELDI) of laser capture microdissection (LCM)-derived cells from cancer tissue. Proc Am Assoc Cancer Res 1999; 40(abs. 2717): 411.
24. Emmert-Buck MR et al. Protein fingerprinting of LCM-dissected human esophageal and prostate cancer by 2D-PAGE. Proc Am Assoc Cancer Res 1999; 40(abs. 3470): 526.
25. Banks RE et al. The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis: preliminary findings. Electrophoresis 1999; 20: 689-700.
26. Frears ER et al. The role of cholesterol in the biosynthesis of beta-amyloid. NeuroReport 1999; 10: 1699-1705.
27. Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen. Urol Clin N Am 1997; 24: 353-365.